International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 1 , Pages 9-15 , 1 May 2010

Radiochemotherapy With Cetuximab, Cisplatin, and Amifostine for Locally Advanced Head and Neck Cancer: A Feasibility Study

  • Michael I. Koukourakis, M.D.

      Affiliations

    • Department of Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis, Greece
    • Corresponding Author InformationReprint requests to: Michael I. Koukourakis, M.D., Department of Radiotherapy/Oncology, Democritus University of Thrace, PO Box 12, Alexandroupolis 68100, Greece. Tel: (25) 510-74622; Fax: (25) 510-30349
    • ,
  • Pelagia G. Tsoutsou, M.D.

      Affiliations

    • Department of Radiotherapy/Oncology, Democritus University of Thrace, Alexandroupolis, Greece
    • ,
  • Antonios Karpouzis, M.D.

      Affiliations

    • Department of Dermatology, Democritus University of Thrace, Alexandroupolis, Greece
    • ,
  • Maria Tsiarkatsi, M.Sc.

      Affiliations

    • Department of Dermatology, Democritus University of Thrace, Alexandroupolis, Greece
    • ,
  • Ilias Karapantzos, M.D.

      Affiliations

    • Department of ENT Clinic, Democritus University of Thrace, Alexandroupolis, Greece
    • ,
  • Vassilios Daniilidis, M.D.

      Affiliations

    • Department of ENT Clinic, Democritus University of Thrace, Alexandroupolis, Greece
    • ,
  • Constantinos Kouskoukis

      Affiliations

    • Department of ENT Clinic, Democritus University of Thrace, Alexandroupolis, Greece

Received 26 February 2009 ,Revised 21 March 2009 ,Accepted 10 April 2009.

References 

  1. Forastiere AA, Ang KK, Brizel DNY. Head and neck cancers. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, version 2.2008. http://www.nccn.org.
  2. Ang KK. Multidisciplinary management of locally advanced SCCHN: Optimizing treatment outcomes. Oncologist. 2008;13:899–910
  3. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet. 2000;355:949–955
  4. Bourhis J, Amand C, Pignon J-P, et al. Update of MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol. 2004;22(Suppl):5505
  5. Bourhis J, Overgaard J, Audry H, et al. for the Meta-Analysis of Radiotherapy in Carcinomas of Head and Neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368:843–854
  6. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003;362:933–940
  7. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48:7–16
  8. Bourhis J, Lapeyre M, Tortochaux J, et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: A GORTEC trial. J Clin Oncol. 2006;24:2873–2878
  9. Horiot JC, Le Fur R, N'Guyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992;25:231–241
  10. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  12. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–1127
  13. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339–3345
  14. Koukourakis MI, Giatromanolaki A, Danielidis V, Sivridis E. Hypoxia inducible factor (HIF1alpha and HIF2alpha) and carbonic anhydrase 9 (CA9) expression and response of head-neck cancer to hypofractionated and accelerated radiotherapy. Int J Radiat Biol. 2008;84:47–52
  15. Maciejewski B, Majewski S. Dose fractionation and tumour repopulation in radiotherapy for bladder cancer. Radiother Oncol. 1991;21:163–170
  16. Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall treatment time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1996;34:315–322
  17. Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M, Delidou H. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res. 2006;26:2437–2443
  18. Boccia R, Anné PR, Bourhis J, Brizel D, Daly C, Holloway N, et al. Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP). Int J Radiat Oncol Biol Phys. 2004;60:302–309
  19. Eriksen JG, Steiniche T. Overgaard J for the Danish Head and Neck Cancer study group (DAHANCA). The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol. 2005;44:50–58
  20. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006;24:727–735
  21. Giro C, Berger B, Bölke E, Ciernik IF, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes. Radiother Oncol. 2009;90:166–171
  22. Pryor DI, Porceddu SV, Burmeister BH, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 2009;90:166–171
  23. Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24:1072–1078

 Conflict of interest: none.

PII: S0360-3016(09)00659-2

doi: 10.1016/j.ijrobp.2009.04.060

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 1 , Pages 9-15 , 1 May 2010

Article Tools

* Image Usage & Resolution